Malignant Mesothelioma Advances in Pathogenesis Diagnosis and Translational Therapies

Malignant Mesothelioma Advances in Pathogenesis, Diagnosis, and Translational Therapies by Harvey I. Pass, MD Nicholas J. Vogelzang, MD Michele Carbone, MD, PhD. Malignant Mesothelioma Advances in Pathogenesis, Diagnosis, and Translational Therapies complete book pdf free download.

Malignant mesothelioma remains one of the sentinel malignancies of oncology. It has a breathtakingly rapid natural history with a median survival of 6 to 8 months when untreated, is environmentally related, and has such economic and social impact that attorneys specialize in representing only mesothelioma patients. Expert witnesses devote full time to testifying, and governments are forced to consider not only the banning of the environmental agent but also a reappraisal of the whole tort system for compensation to injured victims. Furthermore, its presence in certain populations has changed the mindset of whole communities, such as Libby, Montana, Cappadocia, Turkey, Sarnia, and Ontario. Because of its infrequent occurrence, malignant mesothelioma is considered an orphan disease and managed in an anecdotal fashion in most oncologic practices. Yet this disease has set new scientific paradigms—in the clinic, laboratory, and community. 

This book has been assembled to correct an information “disconnect” about this orphan disease and to raise awareness among scientists everywhere about new concepts in the molecular genetics, epidemiology, and carcinogenesis of mesothelioma. We, as editors and authors, work to spread knowledge about mesothelioma and reverse the disproportionately low amount of NCI funding committed to the study of this cancer. Furthermore, we believe that study of this fascinating disease, while occurring in the context of litigation concerns, should proceed along the same paths that all science takes, following the trail of discovery. Legal issues should have no influence—but sadly often do have—on the direction taken by science and medicine. Content of Malignant Mesothelioma Advances in Pathogenesis, Diagnosis, and Translational Therapies .

• The History of Mesothelioma
• Asbestos-Induced Mesothelioma
• SV40-Mediated Oncogenesis 
• Mesothelioma Carcinogenesis: In vivo Models
•  Mesothelial and Mesothelioma Cell Lines
• Cytogenetics of Malignant Mesothelioma
• Growth Factors and Malignant Mesotheliom
•  Oncogenes and Tumor Suppressor Genes in Malignant Mesothelioma
• Angiogenesis and Mesothelioma
• 10 Immune Status and Mesothelioma 
• Extracellular Matrix and Mesothelioma: Some Clues
• Genomics and Proteomics in Mesothelioma
• Part Three Epidemiology
• Asbestos Mineralogy and Health Effects 
• Molecular Epidemiology of Mesothelioma 
• Malignant Mesothelioma and Erionite 
• Determination of Asbestos Exposure by Pathology and Clinical History
• Mesothelioma and Asbestos Exposure
• From Monkey to Man: The Epidemiologic Evidence of an Association Between Simian Virus 40 and Malignancy
• Causes and Prevention of Technical Artifacts When Studying Simian Virus 40 (SV40) in Human Mesotheliomas
• Molecular Detection of Simian Virus 40 in Human Mesothelioma
• Malignant Mesothelioma Following Radiation 
• Genetics and Human Mesothelioma .
• Part Four Clinical Presentation
• Clinicians’ Approach to Mesothelioma 
• Clinical Presentation and Natural History of Mesothioma: Pleural and Pericardial
• Clinical Presentation and Natural History of Mesothelioma: Abdominal
• Staging of Mesothelioma
• Prognostic Factors in Mesothelioma 
• Radiologic Assessment of Mesothelioma .
• Endoscopic Imaging
• Benign Mesotheliomas, Mesothelial Proliferations, andTheir Possible Association with Asbestos Exposure .
• Cytology of Malignant Mesothelioma 
• Malignant Mesothelioma Electron Microscopy 
• Rare Variants of Mesothelioma
• Differentiating Sarcomas from Mesotheliomas
• Diagnosis of Synovial Sarcoma of the Pleura and Differentiation from Malignant Mesothelioma
• Pitfalls in the Diagnosis of Malignant Mesothelioma
•  Management of Benign Variants of Mesothelioma
• First-Line Chemotherapy for Malignant
• Pleural Mesothelioma
• Second-Line Chemotherapy
• Treatment of Mesothelioma with Radiotherapy
• Intrapleural Chemotherapy with and Without Surgery in Malignant Pleural Mesothelioma (MPM)
• Management of Pleural Effusions in Mesothelioma
• Preoperative Chemotherapy and Surgery
• Photodynamic Therapy for Pleural Mesothelioma 
• Surgery and Postoperative Radiotherapy .
• The Development of the Brigham and Women’s
• Multimodality Treatment Plan for Malignant Pleural
• Mesothelioma: A Model for Improving the Treatment of Rare Diseases
• Peritoneal Mesothelioma: The Columbia Experience
• Surgery, Hyperthermic Chemoperfusion, and Postoperative Chemotherapy: The National Cancer
• Institute and Washington Hospital Center Experience 
• Pericardial and Tunica Vaginalis Mesothelioma
• New Target Therapies for Malignant Mesothelioma 
• Gene Therapy for Malignant Pleural Mesothelioma 
• Immunotherapeutic Approaches and Vaccination Strategies 
• Economic Aspects of Mesothelioma